.png | CAS_number = 29767-20-2 | ATC_prefix = L01 | ATC_suffix = CB02 | ATC_supplemental = | PubChem = 34698 | DrugBank = APRD00649 | chemical_formula = C₃₂H₃₂O₁₃S | molecular_weight = 656.655 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 5 hours | pregnancy_category = | legal_status = | routes_of_administration = }} Teniposide is a medication prescribed mainly used to treat childhood acute lymphocytic leukemia. It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body. Common side effects include nausea, vomiting, diarrhea, and thinned or brittle hair. Its brand name is "Vumon" and it is also known as VM-26.

The medication is injected though a vein and burns if it leaks under the skin. It is sometimes used in combination with other anticancer drugs.

A major problem with Teniposide is the lowered count of white blood cells 1-2 weeks after treatment. Though they should return to normal after 3-4 weeks, the decreased count puts a user at a risk of infection. The same also occurs for platelets.